Isolated Limb Perfusion in Regional Melanoma

Surgical Oncology Clinics of North America

Volumn 15, Issue 2, 2006, Pages 373-384

  Noorda, Eva M ^a   Vrouenraets, Bart C ^b   Nieweg, Omgo E ^c   Kroon, Bin B R ^c  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^c ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; ANTINEOPLASTIC AGENT; DACARBAZINE; GAMMA INTERFERON; MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

AGING; ARTERY CATHETERIZATION; ARTERY CLAMP; BLISTER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CARBON DIOXIDE LASER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG UPTAKE; EDEMA; EPIDERMOLYSIS; ERYTHEMA; HUMAN; HYPERTHERMIC THERAPY; LASER SURGERY; LIMB PERFUSION; LYMPH NODE METASTASIS; MELANOMA; METASTASIS; MICROMETASTASIS; MORTALITY; QUALITY OF LIFE; RELAPSE; REVIEW; SHORT FORM 36; SYSTEMIC DISEASE; TISSUE INJURY; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR VASCULARIZATION; TUMOR VOLUME;

CHEMOTHERAPY, ADJUVANT; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; HUMANS; LOWER EXTREMITY; MELANOMA; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PERFUSION; SKIN NEOPLASMS; UPPER EXTREMITY;

EID: 33646032715     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2005.12.004     Document Type: Review

References (50)

1. Creech Jr. O., Krementz E.T., Ryan R.F., et al. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 148 (1958) 616-632
2. Noorda E.M., Vrouenraets B.C., Nieweg O.E., et al. Isolated limb perfusion: what is the evidence for its use?. Ann Surg Oncol 11 (2004) 837-845
3. Grunhagen D.J., Brunstein F., ten Hagen T.L., et al. TNF-based isolated limb perfusion: a decade of experience with antivascular therapy in the management of locally advanced extremity soft tissue sarcomas. Cancer Treat Res 120 (2004) 65-79
4. Sonneveld E.J., Vrouenraets B.C., van Geel B.N., et al. Systemic toxicity after isolated limb perfusion with melphalan for melanoma. Eur J Surg Oncol 22 (1996) 521-527
5. Wieberdink J., Benckhuysen C., Braat R.P., et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 18 (1982) 905-910
6. Vrouenraets B.C., Kroon B.B.R., Klaase J.M., et al. Severe acute regional toxicity after normothermic or 'mild' hyperthermic isolated limb perfusion with melphalan for melanoma. Melanoma Res 5 (1995) 425-431
7. Vrouenraets B.C., Nieweg O.E., and Kroon B.B. Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg 83 (1996) 1319-1328
8. Lienard D., Ewalenko P., Delmotte J.J., et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10 (1992) 52-60
9. van der Veen A.H., de Wilt J.H., Eggermont A.M., et al. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer 82 (2000) 973-980
10. Nooijen P.T., Manusama E.R., Eggermont A.M., et al. Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Br J Cancer 74 (1996) 1908-1915
11. Koops H.S., Vaglini M., Suciu S., et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. J Clin Oncol 16 (1998) 2906-2912
12. Fenn N.J., Horgan K., Johnson R.C., et al. A randomized controlled trial of prophylactic isolated cytotoxic perfusion for poor-prognosis primary melanoma of the lower limb. Eur J Surg Oncol 23 (1997) 6-9
13. Hafstrom L., Rudenstam C.M., Blomquist E., et al. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group. J Clin Oncol 9 (1991) 2091-2094
14. Klaase J.M., Kroon B.B., van Geel A.N., et al. Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. J Am Coll Surg 178 (1994) 564-572
15. Noorda E.M., Takkenberg B., Vrouenraets B.C., et al. Isolated limb perfusion prolongs the limb recurrence-free interval after several episodes of excisional surgery for locoregional recurrent melanoma. Ann Surg Oncol 11 (2004) 491-499
16. Fraker D.L., Alexander H., Ross M., et al. A phase III trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis factor (TNF) plus interferon gamma. Ann Surg Oncol 9 suppl (2002) S8
17. Rossi C.R., Foletto M., Mocellin S., et al. Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and melphalan for bulky in-transit melanoma metastases. Ann Surg Oncol 11 (2004) 173-177
18. Liénard D., Eggermont A.M., Koops H.S., et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 9 (1999) 491-502
19. Noorda E.M., Vrouenraets B.C., Nieweg O.E., et al. Isolated limb perfusion for unresectable melanoma of the extremities. Arch Surg 139 (2004) 1237-1242
20. Grunhagen D.J., Brunstein F., Graveland W.J., et al. One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases. Ann Surg 240 (2004) 939-947
21. Hill S., and Thomas J.M. Use of the carbon dioxide laser to manage cutaneous metastases from malignant melanoma. Br J Surg 83 (1996) 509-512
22. Strobbe L.J., Nieweg O.E., and Kroon B.B. Carbon dioxide laser for cutaneous melanoma metastases: indications and limitations. Eur J Surg Oncol 23 (1997) 435-438
23. Overgaard J., Gonzalez G.D., Hulshof M.C., et al. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Lancet 345 (1995) 540-543
24. Storm F.K., Sparks F.C., and Morton D.L. Treatment for melanoma of the lower extremity with intralesional injection of bacille Calmette Guerin and hyperthermic perfusion. Surg Gynecol Obstet 149 (1979) 17-21
25. von Wussow P., Block B., Hartmann F., et al. Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 61 (1988) 1071-1074
26. Strobbe L.J., Hart A.A., Rumke P., et al. Topical dinitrochlorobenzene combined with systemic dacarbazine in the treatment of recurrent melanoma. Melanoma Res 7 (1997) 507-512
27. Thompson J.F., Hunt J.A., Shannon K.F., et al. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg 132 (1997) 903-907
28. Klaase J.M., Kroon B.B., van Geel A.N., et al. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 115 (1994) 39-45
29. Klop W.M., Vrouenraets B.C., van Geel B.N., et al. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. J Am Coll Surg 182 (1996) 467-472
30. Bartlett D.L., Ma G., Alexander H.R., et al. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer 80 (1997) 2084-2090
31. Feldman A.L., Alexander Jr. H.R., Bartlett D.L., et al. Management of extremity recurrences after complete responses to isolated limb perfusion in patients with melanoma. Ann Surg Oncol 6 (1999) 562-567
32. Noorda E.M., Vrouenraets B.C., Nieweg O.E., et al. Repeat isolated perfusion with TNF and melphalan for recurrent limb melanoma. Eur J Surg Oncol 30 (2004) 130
33. Vrouenraets B.C., Eggermont A.M., Hart A.A., et al. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone. Eur J Surg Oncol 27 (2001) 390-395
34. Vrouenraets B.C., Kroon B.B., Ogilvie A.C., et al. Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Ann Surg Oncol 6 (1999) 405-412
35. Sonneveld E.J., Vrouenraets B.C., van Geel B.N., et al. Systemic toxicity after isolated limb perfusion with melphalan for melanoma. Eur J Surg Oncol 22 (1996) 521-527
36. Thomas D.R., and Ritchie C.S. Preoperative assessment of older adults. J Am Geriatr Soc 43 (1995) 811-821
37. Polanczyk C.A., Marcantonio E., Goldman L., et al. Impact of age on perioperative complications and length of stay in patients undergoing noncardiac surgery. Ann Intern Med 134 (2001) 637-643
38. Bonenkamp J.J., Songun I., Hermans J., et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 25 345 (1995) 745-748
39. Hobler K.E. Colon surgery for cancer in the very elderly. Cost and 3-year survival. Ann Surg 203 (1986) 129-131
40. Vrouenraets B.C., In't Veld G.J., Nieweg O.E., et al. Long-term functional morbidity after mild hyperthermic isolated limb perfusion with melphalan. Eur J Surg Oncol 25 (1999) 503-508
41. Noorda E.M., Vrouenraets B.C., Nieweg O.E., et al. Safety and efficacy of isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol 9 (2002) 968-974
42. van Etten B., van Geel A.N., de Wilt J.H., et al. Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors. Ann Surg Oncol 10 (2003) 32-37
43. Balch C.M., Soong S.J., Gershenwald J.E., et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19 (2001) 3622-3634
44. Vrouenraets B.C., Eggermont A.M., Klaase J.M., et al. Long-term neuropathy after regional isolated perfusion with melphalan for melanoma of the limbs. Eur J Surg Oncol 20 (1994) 681-685
45. Vrouenraets B.C., Klaase J.M., Kroon B.B., et al. Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Arch Surg 130 (1995) 43-47
46. Gotay C.C., and Muraoka M.Y. Quality of life in long-term survivors of adult-onset cancers. J Natl Cancer Inst 90 (1998) 656-667
47. Ramsey S.D., Berry K., Moinpour C., et al. Quality of life in long term survivors of colorectal cancer. Am J Gastroenterol 97 (2002) 1228-1234
48. Ganz P.A., Coscarelli A., Fred C., et al. Breast cancer survivors: psychosocial concerns and quality of life. Breast Cancer Res Treat 38 (1996) 183-199
49. van Tulder M.W., Aaronson N.K., et al. The quality of life of long-term survivors of Hodgkin's disease. Ann Oncol 5 (1994) 153-158
50. Noorda E.M., van Kreij R.H.J., Vrouenraets B.C., et al. Quality of life in long-term survivors after perfusion for melanoma of the limbs. Ann Surg Oncol 11 Suppl (2004) S76